Comparison of Prophylactic and Therapeutic Liposomal Amphotericin B (LAmB) Treatment in Murine Pulmonary Aspergillosis (PA).

D. S. CONSTABLE, J. A. OLSON, P. J. SMITH, J. P. ADLER-MOORE;

Author address: 

California State Polytechnic Univ., Pomona, CA.

Abstract: 

Background: Treatment of PA is complicated by delayed diagnosis in high risk immunosuppressed patients. With sustained LAmB tissue levels, we hypothesized that LAmB prophylaxis (Pro) could result in early drug contact with the fungus. Therefore, in this study we compared LAmB as Pro or early therapy (Tx) for murine PA. Methods: DBA/2 mice were treated IV with Pro, LAmB 15mg/kg 3x/wk for 2 wk (90mg/kg total); Pro + Tx, LAmB 15mg/kg 3x/wk for 2 wk plus 10mg/kg 24h post challenge (pc); Tx, LAmB 10mg/kg 24h pc; Early Tx, LAmB or Amphotericin B lipid complex (ABLC) 20mg/kg at 2h, 24h, 48h, 72h pc. Mice were immunosuppressed IP with Triamcinolone (2.0 mg/kg) -3d, 0d and 2d and challenged intranasally with 106-108 A. fumigatus d0. Mean Log10 CFU/g lung were determined on d3 pc (n=5/gp) and survival (n=7/gp) was monitored for 9 days. Results: In the survival experiment, 20mg/kg LAmB Tx begun 2h pc and repeated for 3d produced significantly (P
2006

abstract No: 

M-1749

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th